WATERTOWN, Mass.—EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharma developing innovative ophthalmic products, has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI). The move became effective late last month. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ market that are classified as either biotech or pharmaceutical, according to the Industry Classification Benchmark (ICB). In a commercial update issued earlier this month, EyePoint said it expects to launch the two new products—Yutiq and Dexycu—in the first quarter, as VMAIL reported. 

The company provided a 2019 commercial update in which president and chief executive officer Nancy Lurker said EyePoint expects to launch the two new products—Yutiq and Dexycu—in the first quarter of this year.

Dexycu (dexamethasone intraocular suspension) 9% was approved by the Food and Drug Administration (FDA) on Feb. 9, 2018, and is the first and only FDA-approved single-dose, sustained-release, intracameral steroid for the treatment of postoperative inflammation.Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg received FDA approval on Oct. 12, 2018, and is the first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of blindness in the U.S., according to EyePoint.

EyePoint Pharmaceuticals was formerly known as pSivida Corp. It is committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.